跳到正文
制药经理人· GxP知识岛·· 10 天前AI 评分55

PIC/S 委员会于 2026 年 11 月 2 日通过《药品检查合作计划章程》修订版 PIC/S 1/95(Rev. 7)

PIC/S 修订《药品检查合作计划章程》Rev.7!

AI 导读

PIC/S 于 2026 年 11 月 12 日发布消息,其委员会已于 11 月 2 日在伊斯坦布尔会议上通过《药品检查合作计划章程》修订版 PIC/S 1/95(Rev. 7)。章程规定 PIC/S 依瑞士民法典设立为协会,并明确信息共享应完全自愿,参与当局无义务共享信息或接受其他参与当局的结论。

正文

2026年11月12日,PIC/S 在官网发布消息:委员会已于11月2日在土耳其伊斯坦布尔举行的会议上,通过修订后的《药品检查合作计划章程》(PIC/S 1/95(Rev. 7))。翻译如下:

以下为全文中英对照。

Preamble

序言

We, the Members of the Pharmaceutical Inspection Co-operation Scheme (PIC/S),

我们,药品检查合作计划(PIC/S)的各成员,

Having considered that medicinal products, whether exported or not, should be produced according to appropriate standards in the interest of public health, whether for humans or animals;

考虑到药品无论是否出口、无论供人用还是兽用,都应当按适当标准生产,以维护公众健康;

Recognising that in order to protect public health, the manufacturing of medicinal products necessitates strict quality management, which can only be ensured by independent, third-party inspections carried out by Regulatory Authorities (RA);

认识到为保护公众健康,药品生产必须有严格的质量管理,而这只能由药品监管机构(RA)实施的独立第三方检查来保证;

Determined to have effective Good Manufacturing Practices Regulatory Compliance Programme (GMPRCP) in place, which comply with strict quality management system requirements;

决心建立有效的药品生产质量管理规范合规计划(GMPRCP),并使其符合严格的质量管理体系要求;

Having considered that PIC/S offers an effective platform to respond to the challenges of globalisation and to promote inspection reliance that strengthen supply resilience, it becomes essential to further increase harmonisation efforts in setting regulatory requirements. This is done by inspecting and evaluating compliance notably with Good Manufacturing Practice (GMP), licensing manufacturing sites, identifying and recalling defective batches;

考虑到PIC/S为应对全球化挑战、促进检查依赖以增强供应韧性提供了有效平台,在制定监管要求方面进一步加大趋同努力已属必要。这主要通过检查和评价GMP合规情况、对生产场地发放许可、识别和召回缺陷批次来实现;

Recognising that such efforts require increased co-operation and reliance between RA, whether they are Members of PIC/S or not;

认识到这些努力要求各监管机构之间——无论是否为PIC/S成员——加强合作与相互依赖;

Have agreed on the following:

达成一致如下:

Articles 1–6: Legal status and definitions

第1–6条 法律地位与定义

1. PIC/S is hereby established as an Association under the Swiss Code of Civil Law (Art. 60 and following). It is legally registered in Geneva (Switzerland) with the "Registre du Commerce" under the name "Pharmaceutical Inspection Co-operation Scheme – Association de Droit Suisse" (Swiss federal no: CH-660.9.587.004-3) and consequently subject to Swiss law.

1. PIC/S依瑞士民法典(第60条及以下各条)设立为协会,以“Pharmaceutical Inspection Co-operation Scheme – Association de Droit Suisse”之名在日内瓦(瑞士)商业登记簿完成法律登记(瑞士联邦编号:CH-660.9.587.004-3),因此受瑞士法律管辖。

2. Although international by its membership and activities, PIC/S does not have the legal status of an International Organisation, as defined under Public International Law.

2. 尽管成员与活动均具国际性,PIC/S并不具备国际公法意义上国际组织的法律地位。

3. PIC/S is a purely scientific and technical organisation. It is a non-political, non-discriminatory organisation. All Members have the same rights and obligations.

3. PIC/S是纯粹的科学与技术性组织,是非政治性、无歧视性的组织。所有成员权利义务相同。

4. The working language of PIC/S is English. These Articles may be prepared in French and English. For registration with the Geneva Commercial Register, the French version shall be used. For the internal governance and operation of PIC/S, the English version shall be used as the working version, provided that it shall be interpreted consistently with the registered French version.

4. PIC/S的工作语言为英语。本章程可备有法文本和英文本。向日内瓦商业登记处登记时使用法文本;PIC/S的内部治理与运作以英文本为工作文本,但对其解释应与已登记的法文本保持一致。

5. PIC/S is a legally non-binding arrangement between RA, or other bodies representing those, competent to inspect medicinal products in the field of Good Manufacturing Practice (GMP).

5. PIC/S是有能力在药品生产质量管理规范(GMP)领域检查药品的监管机构(RA)或其代表机构之间达成的、不具法律约束力的安排。

6. For the purpose of PIC/S,

6. 就PIC/S而言,

- "medicinal product" means: (a) any pharmaceutical, medicine or similar product intended for human or veterinary use which is subject to control by health legislation, and (b) any active pharmaceutical ingredient (API) or excipient which the manufacturer uses in the manufacture of a product referred to in sub-paragraph (a) above.

——“药品”指:(a) 受卫生立法管控、供人用或兽用的任何药剂、药品或类似产品;(b) 生产商用于制造上述(a)项产品的任何原料药(API)或辅料。

- "Good Manufacturing Practices regulatory compliance programme" (GMPRCP) means the overall system established by a Regulatory Authority to ensure compliance with Good Manufacturing Practices, including the GMP inspection process and the associated legislative, regulatory, organisational and quality system arrangements.

——“药品生产质量管理规范合规计划”(GMPRCP)指监管机构为确保符合GMP而建立的整套体系,包括GMP检查过程及相关的立法、监管、组织和质量体系安排。

- "Regulatory Authority" (RA) means (i) a competent Authority in charge of the GMPRCP; (ii) another body deemed equivalent by the PIC/S Committee.

——“监管机构”(RA)指:(i) 负责GMPRCP的主管机构;(ii) 经PIC/S委员会认定等同的其他机构。

- "Participating Authority" (PA) means a RA, which has applied for PIC/S membership, has been found to comply with PIC/S requirements, and has acceded to PIC/S. For the List of Participating Authorities, see the PIC/S website (https://www.picscheme.org).

——“参与当局”(PA)指已申请加入PIC/S、经认定符合PIC/S要求并已正式加入的监管机构。参与当局名单见PIC/S网站(https://www.picscheme.org)。

- "Participating Organisation" (PO) means an organisation other than a RA that performs inspections based on legislation, which has applied for PIC/S membership, has been found to comply with ad-hoc PIC/S requirements, and has acceded to PIC/S. For the List of Participating Organisations, see the PIC/S website (https://www.picscheme.org).

——“参与组织”(PO)指监管机构以外、依法律开展检查的组织,其已申请加入PIC/S、经认定符合PIC/S的专门要求并已正式加入。参与组织名单见PIC/S网站(https://www.picscheme.org)。

For the purposes of this document, references to a Participating Authority also include a Participating Organisation (PO), unless explicitly stated otherwise.

就本文件而言,凡提及“参与当局”,除另有明文规定外,也包括参与组织(PO)。

- "Associated Partner" means a Regulatory Authority or International Organisation (or part of it) which is important to PIC/S, can significantly contribute to PIC/S' goals; and has concluded a Non-Binding Partnership with PIC/S.

——“关联伙伴”(Associated Partner)指对PIC/S具有重要性、能显著促进PIC/S目标实现,并已与PIC/S缔结非约束性伙伴关系的监管机构或国际组织(或其组成部分)。

- "Members" means a Participating Authority or a Participating Organisation that adheres to the PIC/S.

——“成员”指加入PIC/S的参与当局或参与组织。

- "The Directorate" means those persons in charge of directing and managing staff to whom those responsibilities have been delegated by the Executive Bureau of PIC/S.

——“行政管理层”(The Directorate)指受PIC/S执行局委托、负责指导和管理人员并承担相应职责的人员。

I. Mission and Purpose

一、使命与宗旨

7. PIC/S' mission is to protect public health by leading the international development, implementation and maintenance of harmonised GMP standards and quality management systems of inspectorates in the field of medicinal products. This is to be achieved by developing and promoting harmonised GMP standards and guidance documents; offering world class training to inspectors of Regulatory Authorities; assessing (and reassessing) inspectorates; and facilitating the co-operation and networking for RA and international bodies.

7. PIC/S的使命是保护公众健康,途径是引领药品领域检查机构协调一致的GMP标准和质量管理体系的国际制定、实施与维护。具体通过以下方式实现:制定并推广协调一致的GMP标准与指南文件;为监管机构检查员提供世界级培训;对检查机构进行评估(及再评估);促进监管机构与国际机构的合作与联络。

8. The purpose of PIC/S is, with due regard to public health,

8. PIC/S的宗旨是,在适当顾及公众健康的前提下:

(a) to pursue and strengthen the co-operation established between the Participating Authorities and to foster the collaboration with international regulatory and harmonisation bodies in the field of inspection related to the manufacture of medicinal products and associated activities, aimed at maintaining mutual confidence, enabling mutual reliance, enhancing global convergence, and promoting quality of inspections,

(a) 推进并巩固参与当局之间已建立的合作,促进与国际监管和协调机构在药品生产检查及相关活动领域的协作,以保持相互信任、实现相互依赖、增进全球趋同、提升检查质量;

(b) to provide the framework for sharing information and experiences on a voluntary basis,

(b) 为在自愿基础上共享信息和经验提供框架;

(c) to co-ordinate and deliver training for inspectors and other technical experts in related fields. In particular, the PIC/S Inspectorates' Academy (PIA) promotes harmonised training, supports uniform qualification processes, and enhances inspection excellence across PA,

(c) 为检查员及相关领域其他技术专家协调并组织培训。特别是PIC/S检查员学院(PIA)推动协调一致的培训、支持统一的资格认定流程,并提升各参与当局的检查水平;

(d) to continue common efforts towards the improvement and harmonisation of technical standards and procedures regarding the inspection of the manufacture of medicinal products by PAs,

(d) 继续共同努力,改进和协调各参与当局在药品生产检查方面的技术标准与程序;

(e) to continue common efforts for the development, harmonisation and maintenance of GMP, and

(e) 继续共同努力,开发、协调和维护GMP;

(f) to extend the co-operation to other RA having the necessary arrangements in place to apply equivalent standards and procedures with a view to contributing to global harmonisation.

(f) 把合作扩展到已具备必要安排、能够适用同等标准和程序的其他监管机构,以促进全球协调一致。

II. Membership requirements

二、成员要求

9. PIC/S is open for participation by RA having the arrangements necessary to apply a GMPRCP comparable to that enforced by Participating Authorities and whose requirements and procedures are such as to ensure the proper implementation of PIC/S and contribute to its effective operation.

9. PIC/S向具备必要安排、能够实施与参与当局相当的GMPRCP的监管机构开放;该机构的要求与程序须能确保PIC/S得到正确实施,并有助于其有效运作。

10. The RA should notably ensure that:

10. 监管机构尤其应确保:

(a) the inspectors in their service have received appropriate training, qualifications and experience for the tasks to be undertaken by them,

(a) 其检查员已接受与所承担任务相适应的培训,并具备相应资格和经验;

(b) the inspectors and/or the control laboratories have the power to call for the submission of quality control records and, where appropriate, samples relating to any batch of any medicinal products,

(b) 检查员和/或控制实验室有权要求提交质量控制记录,并在适当时要求提交与任何药品任何批次有关的样品;

(c) the inspectorate utilises the PIC/S GMP Guide (or equivalent) as well as other current guides, guidelines, explanatory notes and recommendations, adopted by PIC/S and available at http://www.picscheme.org, as the basis for inspections and authorisation of manufacturers,

(c) 检查机构以PIC/S GMP指南(或同等文件)以及PIC/S通过并在其网站(http://www.picscheme.org)公布的其他现行指南、指导原则、解释性说明和建议,作为检查和批准生产商的依据;

(d) the operation of the GMPRCP is subject to a system of quality management aimed at ensuring the maintenance of necessary standards.

(d) GMPRCP的运作受质量管理体系约束,以确保必要标准得以维持。

11. RA or other organisations, which have applied for PIC/S membership and successfully completed the applicable accession process, are invited by the PIC/S Committee to become PIC/S Participating Authorities (for further details, see Chapter V). The GMPRCP of each Participating Authority should be re-evaluated on a regular basis in line with the PIC/S Joint Reassessment Programme or equivalent programmes.

11. 已申请加入PIC/S并成功完成相应加入程序的监管机构或其他组织,由PIC/S委员会邀请成为PIC/S参与当局(详见第五章)。各参与当局的GMPRCP应按PIC/S联合再评估计划或同等计划定期再评估。

III. Organisation

三、组织

12. The effective operation and application of PIC/S shall be ensured by the PIC/S Committee, the Executive Bureau and the Secretariat.

12. PIC/S的有效运作与实施由PIC/S委员会、执行局和秘书处保证。

13. Representatives of participating authorities who are members of the PIC/S Committee and the Executive Bureau serve on a voluntary basis (non-paid) for PIC/S. They are not entitled to reimbursement by PIC/S of their actual expenses or travel expenses incurred in the ordinary course of their usual duties for PIC/S, nor to any attendance fees. For tasks that go beyond the usual scope of the role for PIC/S, each member may not only claim reimbursement of his or her actual expenses and travel expenses, but may also receive appropriate compensation.

13. 在PIC/S委员会和执行局任职的参与当局代表,以自愿(无报酬)方式为PIC/S服务。对其为PIC/S履行通常职责过程中实际发生的费用和差旅费,PIC/S不予报销,也不支付出席费。对超出其通常职责范围的任务,各成员既可报销实际费用和差旅费,也可获得适当报酬。

14. Paid employees of PIC/S may sit on the PIC/S Committee and the Executive Bureau only in an advisory (non-voting) capacity.

14. PIC/S的受薪雇员只能以咨询(无表决权)身份列席PIC/S委员会和执行局。

The PIC/S Committee

PIC/S委员会

15. A permanent Committee composed of representatives of the Participating Authorities should meet whenever necessary but at least once a year in order to:

15. 由参与当局代表组成的常设委员会应在必要时召开会议,但每年至少一次,以便:

(a) consider measures for achieving the appropriate and effective operation of PIC/S;

(a) 审议使PIC/S恰当、有效运作的各项措施;

(b) make recommendations and proposals for the amendment, updating and improvement of (i) GMP standards currently applied by PIC/S; and (ii) any other GxP standards or Good Practices applied on a voluntary basis;

(b) 就以下内容的修订、更新与改进提出建议和提案:(i) PIC/S现行适用的GMP标准;(ii) 自愿适用的任何其他GxP标准或良好规范;

(c) promote co-operation between the Participating Authorities to facilitate the application of PIC/S;

(c) 促进参与当局之间的合作,便利PIC/S的实施;

(d) exchange information and experience on means and methods for achieving uniform and effective inspections;

(d) 就实现统一、有效检查的手段和方法交流信息与经验;

(e) promote quality management systems for the GMPRCP;

(e) 推广适用于GMPRCP的质量管理体系;

(f) promote training for inspectors by means of e.g.: - the PIC/S Inspectorates' Academy (PIA), - seminars, expert circles dealing with the state of the art of GMP knowledge in all necessary fields, and - joint visits for the harmonisation of inspections;

(f) 通过以下方式推动检查员培训:PIC/S检查员学院(PIA);研讨各必要领域GMP最新知识的研讨会和专家圈;为统一检查而开展的联合访问;

(g) promote the exchange of experience in relation to GMP for special categories of medicinal products e.g. human blood and tissue, medicinal gases, radiopharmaceuticals, hospital pharmacy, biotechnologically manufactured medicinal products, Advanced Therapy Medicinal Products (ATMPs);

(g) 促进就特殊类别药品的GMP交流经验,例如人血液和组织、医用气体、放射性药品、医院药房、生物技术生产的药品、先进治疗药物(ATMP);

(h) promote the transfer of knowledge and experience among Participating Authorities through structured mechanisms supporting continuity, capacity building, and PIC/S memory;

(h) 通过支持连续性、能力建设和PIC/S经验传承的结构化机制,促进参与当局之间的知识与经验传递;

(i) discuss and decide on the accession and Pre-Accession of RA to PIC/S;

(i) 讨论并决定监管机构加入PIC/S及预加入事宜;

(j) make proposals for amendments to the PIC/S Scheme to ensure it remains up to date;

(j) 为修订PIC/S章程提出提案,使其保持时效;

(k) contribute to the development of new guides and guidance documents applicable to GMP e.g. for different types of manufactures;

(k) 参与制定适用于GMP的新指南和指导文件,例如针对不同类型生产商的指南;

(l) promote global harmonisation of GMP;

(l) 推动GMP的全球协调一致;

(m) adopt annual budgets and approve financial accounts in line with financial rules;

(m) 按财务规则通过年度预算并批准财务账目;

(n) elect the Executive Bureau;

(n) 选举执行局;

(o) negotiate and conclude agreements.

(o) 谈判并缔结协议。

16. The Committee may delegate parts of its powers to the Executive Bureau and remains free to revoke such delegations at any time. The Committee remains responsible for the diligence exercised in the selection, instruction, and supervision of the Sub-Committees Chairs who are de facto members of the Executive Bureau.

16. 委员会可将其部分权力委托给执行局,并可随时自行撤销该等委托。对于实为执行局成员的各小组委员会主席,委员会对其遴选、指示和监督中所尽的勤勉义务仍承担责任。

17. The Committee should adopt its own rules of procedure as well as financial rules.

17. 委员会应通过自身的议事规则和财务规则。

18. Associated Partner Organisations are invited to attend Committee meetings. The Committee also invites representatives from RA, which are in the process of acceding or intend to accede to PIC/S, to attend meetings as guests.

18. 关联伙伴组织受邀出席委员会会议。委员会还邀请正在办理加入或拟加入PIC/S的监管机构代表作为嘉宾出席。

19. The annual accounts, drawn up at the end of each financial year, shall be reviewed by the supervisory body appointed by the Committee, which shall submit a written report. On the basis of this report, the Committee shall approve the accounts and decide on the discharge of the Executive Bureau and the Secretariat for the past financial year. The discharge shall only apply to facts known at the time of its granting.

19. 每一财政年度结束时编制的年度账目,应由委员会指定的监督机构审阅,该机构应提交书面报告。委员会据此批准账目,并决定是否解除执行局和秘书处上一财政年度的责任。解除责任仅适用于作出解除时已知悉的事实。

The PIC/S Executive Bureau

PIC/S执行局

20. The Executive Bureau should meet at least three times per year, in-between meetings of the Committee, and as often as necessary in order to:

20. 执行局应在委员会会议之间每年至少开会三次,并按需要随时开会,以便:

(a) supervise PIC/S' Sub-Committees activities notably in order to ensure their coherence;

(a) 监督PIC/S各小组委员会的活动,特别是确保其协调一致;

(b) implement Committee decisions and define the Committee's agenda with the assistance of the Secretariat;

(b) 在秘书处协助下执行委员会决定,并确定委员会议程;

(c) ensure the alignment of strategy and resources as well as propose strategic orientations and facilitate decision-making;

(c) 确保战略与资源相匹配,提出战略方向并便利决策;

(d) oversee the organisation of the accounts, financial audits and financial planning including the annual budget in line with financial rules;

(d) 按财务规则监督账目、财务审计和财务规划(含年度预算)的组织工作;

(e) define internal organisational structure and maintain it up to date;

(e) 确定内部组织结构并保持其更新;

(f) engage and dismiss the Directorate, subject to the Committee approval and decide upon representation powers including for entities dependent on PIC/S;

(f) 经委员会批准聘任和解聘行政管理层,并决定包括PIC/S附属实体在内的代表权;

(g) ensure the proper management of the Secretariat, which is carried out by the Directorate;

(g) 确保由行政管理层实施的秘书处管理得当;

(h) supervise the management of PIC/S in compliance with Swiss law, the PIC Scheme and its regulations;

(h) 监督PIC/S的管理符合瑞士法律、PIC章程及其规定;

(i) assume tasks and exercise powers not expressly delegated for Sub-Committees for the unobstructed functioning of PIC/S.

(i) 承担未明确授予小组委员会的任务并行使相应权力,以保障PIC/S运转顺畅。

21. The members of the Executive Bureau may validly make decisions in person, by video or telephone conference, or by any other means decided by the Committee. In-person meetings may be held in Switzerland or abroad.

21. 执行局成员可以亲临、以视频或电话会议,或以委员会决定的其他方式有效作出决定。亲临会议可在瑞士境内或境外举行。

22. The Executive Bureau reports to the PIC/S Committee. The composition and election of the Executive Bureau are defined in the rules of procedure.

22. 执行局向PIC/S委员会报告。执行局的组成与选举在议事规则中规定。

23. In agreement with PIC/S Committee, the Executive Bureau may delegate part of its powers to Sub-Committees and remains free to revoke such delegations at any time. The Executive Bureau remains responsible for the diligence exercised in the instruction and supervision of the Sub-Committees.

23. 经与PIC/S委员会商定,执行局可将其部分权力委托给各小组委员会,并可随时自行撤销。执行局对小组委员会的指示和监督中所尽的勤勉义务仍承担责任。

The PIC/S Secretariat

PIC/S秘书处

24. A Secretariat should be established by the Committee to support and facilitate the implementation of the PIC/S mission. It may also provide secretariat services to other organisations.

24. 委员会应设立秘书处,以支持和便利PIC/S使命的落实。秘书处也可向其他组织提供秘书服务。

25. The Secretariat is managed by the Directorate.

25. 秘书处由行政管理层管理。

External auditors

外部审计

26. PIC/S must submit its accounts to regular audit by an auditing body if, during two consecutive financial years, two of the following values are exceeded: 1) Total balance sheet: 10 million of francs; 2) Turnover: 20 millions of francs; 3) Workforce: 50 full-time jobs on average per year.

26. 如在连续两个财政年度内超过下列数值中的两项,PIC/S必须将其账目交由审计机构作定期审计:1) 资产负债表总额:1000万瑞士法郎;2) 营业额:2000万瑞士法郎;3) 员工人数:平均每年50个全职岗位。

27. PIC/S must submit its accounts to a limited audit by an auditing body if a member of the association who is individually liable or required to make additional payments so requests.

27. 如协会成员中负有单独责任或有追加缴付义务者提出要求,PIC/S必须将其账目交由审计机构作有限审计。

28. All persons responsible for auditing the annual and consolidated accounts are liable to PIC/S and to each of its members for any damage caused by an intentional or negligent breach of their obligations (art. 755 al. 1 Swiss Code of Obligations).

28. 所有负责审计年度账目和合并账目的人员,因故意或过失违反义务造成损害的,对PIC/S及其每一成员承担责任(瑞士债法典第755条第1款)。

IV. Amendments

四、修订

29. The PIC/S Scheme may be amended by unanimous consent of the Participating Authorities.

29. PIC/S章程须经参与当局一致同意方可修订。

V. Accession and Pre-Accession

五、加入与预加入

30. A RA, as defined in paragraph 5, may submit a request for accession in PIC/S, expressing consent to accept PIC/S. The request should be addressed to the Secretariat together with information required under the Guidelines for Accession to PIC/S.

30. 第5条所定义的监管机构可提交加入PIC/S的申请,表示同意接受PIC/S。申请应连同《PIC/S加入指南》所要求的信息一并递交秘书处。

31. The Secretariat should inform all Participating Authorities of the request.

31. 秘书处应将申请通知所有参与当局。

32. The Committee should decide on the accession of a RA in PIC/S. Such decision requires the consent of all Participating Authorities.

32. 委员会应就监管机构加入PIC/S作出决定。该决定须经所有参与当局同意。

33. The participation should become effective on a date determined by the Committee.

33. 参与自委员会确定的日期起生效。

34. The Secretariat should communicate the effective date of the participation to all parties concerned.

34. 秘书处应将参与的生效日期通知所有相关方。

Pre-Accession

预加入

35. A RA wishing to engage in the pre-accession process may submit a request to the Secretariat in accordance with the Guidelines for Pre-Accession to PIC/S.

35. 希望参加预加入程序的监管机构,可按《PIC/S预加入指南》向秘书处提交申请。

VI. Withdrawal

六、退出

36. A Participating Authority may withdraw from PIC/S by giving three months' notice in writing to the Secretariat, which shall inform all the other Participating Authorities.

36. 参与当局可提前三个月书面通知秘书处退出PIC/S,秘书处应通知所有其他参与当局。

VII. Suspension / Exclusion

七、暂停与除名

37. If a Participating Authority no longer fulfils the requirements of the PIC/S Scheme, fails to comply with its obligations, including participation in meetings or financial contributions, or if, through its actions and behaviour, it or its representatives undermine the proper functioning, objectives, or reputation of PIC/S, the Committee may, in accordance with the PIC-PIC/S Committee Rules of Procedure, decide to: - suspend its participation in PIC/S for a specified period; - extend such suspension or - proceed with exclusion from PIC/S, with immediate effect.

37. 如参与当局不再符合PIC/S章程的要求、不履行其义务(包括参加会议或缴纳会费),或其本人或代表的行为损害PIC/S的正常运转、目标或声誉,委员会可按PIC-PIC/S委员会议事规则决定:在指定期限内暂停其参与;延长该暂停;或立即将其从PIC/S除名。

38. The Committee may also suspend or exclude a representative of a PA whose actions or behaviour are incompatible with the objectives, principles, policies, or reputation of PIC/S, including violations of rules of conduct or of the principles of non-politicisation or non-discrimination, as further detailed in the PIC-PIC/S Committee Rules of Procedure.

38. 对于行为与PIC/S的目标、原则、政策或声誉不相容的参与当局代表,委员会同样可予以暂停或除名,包括违反行为准则或违反非政治化、无歧视原则的情形,具体按PIC-PIC/S委员会议事规则执行。

VIII. Termination

八、终止

39. All Participating Authorities may decide to terminate PIC/S by unanimous consent.

39. 全体参与当局可一致同意决定终止PIC/S。

40. In that case, the available assets shall be entirely allocated to another organisation pursuing a public-interest purpose similar to that of PIC/S and which benefits from the tax exemption. Under no circumstances may the assets be returned to the founders, members, donors or their relatives, nor may they be used for their benefit, in whole or in part, and in any way whatsoever.

40. 在此情形下,可用资产应全部拨付给另一家从事与PIC/S类似公益目的并享有免税待遇的组织。任何情况下,资产不得返还创始人、成员、捐赠人或其亲属,也不得全部或部分、以任何方式为其利益使用。

IX. Reoganisation

九、重组

41. The PIC/S Committee should examine on a case-by-case basis the reorganisation of Participating Authorities, notably in the case of merger with or separation from another Authority. The examination should take into account whether an Authority emerging from such reorganisation (i) is the legal successor of the previously Regulatory Authority; (ii) is fully competent (in accordance with paragraph 9 above); and (iii) has retained the Quality Management System and Staff (in accordance with paragraph 10 above).

41. PIC/S委员会应逐案审查参与当局的重组,特别是与另一机构合并或分离的情形。审查应考虑重组后产生的机构:(i) 是否为原监管机构的法律承继者;(ii) 是否完全具备能力(按第9条);(iii) 是否保留了质量管理体系和人员(按第10条)。

42. Authorities emerging from a reorganisation, which are competent in accordance with paragraph 9 above, will be either reassessed under the PIC/S Joint Reassessment Programme (or equivalent) or invited to apply for PIC/S membership.

42. 重组后产生、按第9条具备能力的机构,将在PIC/S联合再评估计划(或同等计划)下接受再评估,或受邀申请加入PIC/S。

X. Sharing of information

十、信息共享

43. This Chapter applies to all information shared in PIC/S, which is classified (e.g. restricted, confidential) in line with PIC/S' classification policy.

43. 本章适用于在PIC/S内共享的、按PIC/S密级政策定级(如受限、保密)的所有信息。

44. In line with the PIC/S Guidance on GMP Inspection Reliance, the sharing of information in PIC/S should be fully voluntary. There is no obligation for a Participating Authority to share information with another Participating Authority.

44. 按《PIC/S GMP检查依赖指南》,PIC/S内的信息共享应当完全自愿。任何参与当局均无义务向另一参与当局共享信息。

45. The aim of sharing information in PIC/S is to facilitate the risk management performed by each Participating Authority on whether or not to carry out an inspection. It gives Participating Authorities the possibility to share in confidence any information e.g. on whether medicinal products have been produced in accordance with the GMP requirements applied in PIC/S or whether such products are due for inspection (so called GMP inspection reliance).

45. PIC/S内信息共享的目的,是便利各参与当局就是否开展检查实施风险管理。它使参与当局能够以保密方式共享任何信息,例如药品是否按PIC/S适用的GMP要求生产、该产品是否到期应检(即所谓GMP检查依赖)。

46. Information shared in PIC/S is not binding for the Participating Authority which has requested it. Each Participating Authority should remain competent on how to use the shared information. There is no obligation to accept the conclusions from another Participating Authority in PIC/S.

46. 在PIC/S内共享的信息,对提出请求的参与当局不具约束力。如何使用共享信息,仍由各参与当局自主决定。没有义务接受PIC/S内另一参与当局的结论。

47. The sharing of information in PIC/S should be subject to legal requirements such as laws, decrees, and treaties – including regional integration treaties (e.g. EU or ASEAN) and Mutual Recognition Agreements. It should not affect the exchange of GMP certificates under such treaties and agreements.

47. PIC/S内的信息共享应服从法律、法令和条约等法律要求,包括区域一体化条约(如欧盟或东盟)和互认协议。它不应影响依据此类条约和协议进行的GMP证书交换。

48. Upon written request of a Participating Authority, the following information can be shared on a purely voluntary basis: GMP compliance, inspection report, corrective action plan, plan of a company, correspondence, follow-up, etc.

48. 应参与当局书面请求,下列信息可在纯自愿基础上共享:GMP合规情况、检查报告、纠正措施计划、企业平面图、往来函件、后续跟进等。

49. Information shared in PIC/S should not extend to: (a) data concerning financial and commercial matters; (b) data concerning technical "know-how" or any other trade secret; (c) data concerning research information; (d) personal data other than those relating to the duties of the persons concerned; (e) information related to an official investigation which may jeopardise enforcement activities.

49. PIC/S内共享的信息不应扩展至:(a) 与财务和商业事务有关的数据;(b) 与技术“专有技术”或任何其他商业秘密有关的数据;(c) 与研究信息有关的数据;(d) 与相关人员职责无关的个人数据;(e) 与可能危及执法活动的官方调查有关的信息。

50. Participating Authorities herewith undertake to respect the confidentiality of information shared in PIC/S. They also undertake to avoid any potential or real conflict of interests with activities and issues under discussion at PIC/S. The undertaking applies to the Participating Authority and to its employees, who shall abide to the Rules of Procedure of the relevant PIC/S bodies.

50. 参与当局特此承诺尊重在PIC/S内共享信息的保密性,并承诺避免与PIC/S正在讨论的活动和议题发生任何潜在或实际的利益冲突。该承诺适用于参与当局及其雇员,后者应遵守相关PIC/S机构的议事规则。

XI. Rapid Alerts and Recalls arising from Quality Defects

十一、质量缺陷引发的快速警报与召回

51. If a Participating Authority discovers in the course of its inspection duties, or otherwise, particular circumstances which cause a medicinal product to be of imminent and serious danger to the public, it shall immediately communicate its findings to the Participating Authorities.

51. 如参与当局在检查职责中或其他情况下发现特定情形,使某药品对公众构成紧迫且严重的危险,应立即将其发现通报各参与当局。

XII. Revenues

十二、收入

52. PIC/S' revenues normally consist of (but not exclusively) from: - annual membership contributions from Participating Authorities, - voluntary donations, - revenues from special services.

52. PIC/S的收入通常(但不限于)来自:参与当局缴纳的年度会费;自愿捐赠;专项服务收入。

53. PIC/S accounts shall be reviewed annually by a supervisory body appointed by the Committee and may be subject to audit in accordance with the applicable statutory requirements.

53. PIC/S账目应由委员会指定的监督机构每年审阅,并可按适用的法定要求接受审计。

Footnotes (as in the original)

原文脚注

1 Some Participating Authorities are not Medicines Regulatory Authorities (e.g. co-ordinating / representing those).

1 部分参与当局并非药品监管机构(例如负责协调或代表这些机构的单位)。

2 Also referred to as "dosage form" or "drug product".

2 亦称“剂型”或“制剂”。

3 Also referred to as "drug substance".

3 亦称“原料药”。

4 See PS/W31/2019.

4 见 PS/W31/2019。

5 See Note [1] above.

5 见上文注1。

6 See Guidelines for Accession to the PIC Scheme (PS/W 14/2011) and related documents.

6 见《加入PIC章程指南》(PS/W 14/2011)及相关文件。

7 See PS/W 9/2025.

7 见 PS/W 9/2025。

8 See PS/W 19/2006.

8 见 PS/W 19/2006。

9 See PE 009.

9 见 PE 009。

10 See the PIC/S Recommendation on Quality System Requirements for Pharmaceutical Inspectorates (PI 002).

10 见《PIC/S 药品检查机构质量体系要求建议》(PI 002)。

11 For the Guidelines for Accession to the PIC Scheme, see PS/W 14/2011 and PS/W 9/2025.

11 关于《加入PIC章程指南》,见 PS/W 14/2011 和 PS/W 9/2025。

12 For the list of Participating Authorities, see the PIC/S website (http://www.picscheme.org).

12 参与当局名单见PIC/S网站(http://www.picscheme.org)。

13 See PS/W 9/2000.

13 见 PS/W 9/2000。

14 E.g. the EU Heads of Agencies "Joint Audit Programme".

14 例如欧盟各国机构负责人“联合审计计划”。

15 In the exercise of these activities account should be taken, where appropriate, of current technical developments and work.

15 开展这些活动时,应酌情考虑当前的技术进展与工作。

16 See PH/PS 9/97.

16 见 PH/PS 9/97。

17 See PS/W 1/2004.

17 见 PS/W 1/2004。

18 See PS/W 1/2006.

18 见 PS/W 1/2006。

19 See PS/W 12/2009.

19 见 PS/W 12/2009。

20 See PS/W 14/2011; PS/W 9/2025.

20 见 PS/W 14/2011;PS/W 9/2025。

21 See PS/W 12/2019.

21 见 PS/W 12/2019。

22 PH/PS 9/97.

22 PH/PS 9/97。

23 See PS/W 12/2006.

23 见 PS/W 12/2006。

24 See PI 048.

24 见 PI 048。

25 This is also applicable for the sharing of information between (i) PIC/S Participating Authorities on the one hand and Regulatory Authorities having applied for membership and Partner Organisations on the other hand; (ii) Competent Authorities having applied for membership and Partner Organisations (and between themselves).

25 本条同样适用于以下主体之间的信息共享:(i) 一方为PIC/S参与当局,另一方为已申请加入的监管机构和伙伴组织;(ii) 已申请加入的主管机构与伙伴组织之间(以及它们彼此之间)。

26 i.e. in accordance with PI 010.

26 即按 PI 010 执行。

来源:制药经理人 · mp.weixin.qq.com

所属事件

查看事件全部
PIC/S 通过并生效 PIC Scheme 第7次修订